WORK EXPERIENCE
01.11.2021 → ongoing
Fully funded PhD student in PhD programme “Network Oncology and Precision Medicine”
Sapienza, University of Rome, Dipartimento di Medicina Sperimentale, Viale regina Elena 324, Rome Italy
Oncology referral for clinical research programs
2021 → 2022
Lecturer - II Level Master in Immuno-Oncologia and II level Master in Senologia
Sapienza, University of Rome
2022
Article reviewer for "Frontiers"
01/11/2016 → 01/11/2021
Resident fellowship as Medical Doctor in training in Medical Oncology
Care and management of patients with solid tumors
"Sapienza" University of Rome – AOU Policlinico Umberto I - UOC Oncologia B
Viale Regina Elena 324, 00161 Rome (Italy)
2015 → 2022
Participation to multidisciplinary meetings “Breast Unit” AOU Policlinico Umberto I
Management of patients affected by breast cancer
AOU Policlinico Umberto I - UOC Oncologia B, Viale Regina Elena 324, 00161 Rome (Italy)
2018 → 2022
Active participation to multidisciplinary meetings “Lung Unit” AOU Policlinico Umberto I
Multidisciplinary management of patients with thoracic malignancies
"Sapienza" University of Rome – AOU Policlinico Umberto I – UOC Oncologia, Viale Regina Elena 324, 00161 Rome (Italy)
2013 → 2015
Medical student
Observation and preclinical research on programme “Molecular linkage between cancer and chronic inflammation”
Sapienza, University of Rome - Laboratory of Immunology, Department of Experimental Medicine, Viale Regina Elena 324, 00161 Rome (Italy)
11/2013 → 12/2015
Medical fellow
Observation of clinical activity and management of patients affected by solid tumors
"Sapienza" University of Rome – AOU Policlinico Umberto I – UOC Oncologia, Viale Regina Elena 324, 00161 Rome (Italy)
10/2012 →11/2013
Medical student
Observation of clinical activity in Sub-Intensive Cardiological Unit
"Sapienza" University of Rome – AOU Policlinico Umberto I – UOC Oncologia, Viale Regina Elena 324, 00161 Rome (Italy)
EDUCATION AND TRAINING
11/11/2021
Specialist in “Medical Oncology”
Score: 70 e lode/70
Thesis: “Analisi di cellule T regolatorie e mieloidi soppressorie circolanti in pazienti affetti da tumore della mammella e del distretto testa-collo metastatici”
Sapienza, University of Rome
Piazzale Aldo Moro 5, 00161 Rome (Italy)
17/03/2016
National Board Exame
Registration to the Provincial Order of Physician of Rome (member n°62245)
Oct 2009 →July 2015
Medicine and Surgery Degree
Score: 110/100 cum laude
Thesis: “Controllo di malattia con tecnica SIRTEX in pazienti affetta da tumore della mammella metastatico”
Sapienza, University of Rome
Piazzale Aldo Moro 5, 00161 Rome (Italy)
ISCED 5
Sep 2004 →July 2009
High school degree
Score: 100/100 cum laude
Liceo classico “A.Torlonia”, Avezzano (AQ) Italy
ISCED 4
SOCIAL SKILLS AND COMPETENCES
- Motivated to work as part of a team or as an individual contributor
- Sense of organization
- Project management
TECHNICAL SKILLS AND COMPETENCES
- Formulate a diagnosis
- Propose a diagnostic and therapeutic plan
- Management of patients affected by solid tumors
- Management of early and advanced breast cancer
- Management of early and advanced thoracic malignancies
- Management of principal medical emergencies
ORGANIZATIONAL SKILLS AND COMPETENCES
- Motivated to work as part of a team or as an individual contributor
- Sense of organization
- Project management
ADDITIONAL INFORMATION
Since 2016 to nowadays I have been attending several clinical trials according to G.C.P as Sub-Investigator:
- Evaluation of a tissue immune profile (TIP) in patients affected by metastatic TNBC treated
with upfront atezolizumab plus nab-paclitaxel;
- JAVELIN BRCA/ATM a phase 2 study to evaluate safety and anti-tumor activity of avelumab in
combination with talazoparib in patients with brca or atm mutant tumors (B9991032);
- COMPLEMENT-1: an open-label multicentre, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatmen of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with no prior hormonal therapy for advanced disease (CLEE011A2402);
- IMPASSION 131: a phase III, multicentre, randomized, double blind, placebo-controlled study of atezolizumab in combination with paclitaxel for patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer (MO30196);
- LUCY: a phase IIIb, single arm, open label multicentre study of Olaparib monotherapy in the treatment of HER2-ve Metastatic Breast Cancer Patients with germline BRCA1/2 mutations (D0816C00018)
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and
Immunotherapy (ROME) (NCT04591431);
-ImPower132: ImPower 132 trial: A phase III, open label, randomized study of Atezolizumab in combination with Carboplatin or Cisplatin + Pemetrexed compared with carboplatin or Cisplatin + Pemetrexed in patients who are chemotherapy-naive and have stage IV non-squamous non small cell lung cancer
-ASCENT‐03: A Randomized, Open‐label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple‐Negative Breast Cancer Whose Tumors Do Not Express PD‐L1 or in Patients Previously Treated With Anti‐PD‐(L)1 Agents in the Early Setting Whose Tumors Do Express PD‐L1, GS‐US‐592‐6238;
-ASCENT 04: A Randomized, Open‐label, Phase 3 Study of Sacituzumab Govitecan and
Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple‐Negative Breast Cancer, Whose Tumors Express PD‐L1; GS‐US‐592‐6173;
-ASCENT 07: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy.
PUBLICATIONS
1. Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments. Nicolazzo C, Gelibter A, Bottillo I, Belardinilli F, Pisegna S, De Renzi G, Marinelli D, Grammatico P, Cortesi E, Giannini G, Gazzaniga P. In: DIAGNOSTICS (Basel). 2021 Nov 25;11(12):2196. doi: 10.3390/diagnostics11122196.
2. Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care? Mazzotta M, Pizzuti L, Krasniqi E, Di Lisa FS, Cappuzzo F, Landi L, Sergi D, Pelle F, Cappelli S, Botti C, Vizza E, Tomao S, Marchetti L, Sanguineti G, Botticelli A, Marchetti P, Magri V, Pisegna S, Venuti A, Tomao F, Buzzacchino F, Ciliberto G, Barba M, Vici P. In: CANCERS (Basel). 2021 Nov 12;13(16):4061. doi: 10.3390/cancers13164061.
3. The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Botticelli, A.; Pomati, G.; Cirillo, A.; Scagnoli, S.; Pisegna, S.; Chiavassa, A.; Rossi, E.; Schinzari, G.; Tortora, G.; Di Pietro, F. R.; Cerbelli, B.; Di Filippo, A.; Amirhassankhani, S.; Scala, A.; Zizzari, I. G.; Cortesi, E.; Tomao, S.; Nuti, M.; Mezi, S.; Marchetti, P. In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 13:(2022). [10.3389/fimmu.2022.974087]
4. Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. Gelibter, Alain; Occhipinti, Mario; Pisegna, Simona; Cortellini, Alessio; Cortesi, Enrico; Marchetti, Paolo. In: LUNG CANCER MANAGEMENT. - ISSN 1758-1966. - 9:2(2020). [10.2217/lmt-2019-0016]
5. Tissue immune profile: a tool to predict response to neoadjuvant therapy in triple negative breast cancer. Cerbelli, B.; Scagnoli, S.; Mezi, S.; De Luca, A.; Pisegna, S.; Amabile, M. I.; Roberto, M.; Fortunato, L.; Costarelli, L.; Pernazza, A.; Strigari, L.; Rocca, C. D.; Marchetti, P.; D’amati, G.; Botticelli, A.. - In: CANCERS. - ISSN 2072-6694. - 12:9(2020), pp. 1-12. [10.3390/cancers12092648]
6. The Strange Case of a Pancreatic Neuroendocrine Carcinoma With Low Proliferation Index and Atypical Clinical Behavior. Feola T, Centello R, Sesti F, Puliani G, Verrico M, Di Vito V, Di Gioia C, Bagni O, Pisegna S, Lenzi A, Isidori AM, Giannetta E, Faggiano A. In: PANCREAS. 2022 Feb 1;51(2):e25-e27. doi:10.1097/MPA.0000000000001999.
7. Botticelli A, Cirillo A, Pomati G, Cortesi E, Rossi E, Schinzari G, Tortora G, Tomao S, Fiscon G, Farina L, Scagnoli S, Pisegna S, Ciurluini F, Chiavassa A, Amirhassankhani S, Ceccarelli F, Conti F, Di Filippo A, Zizzari IG, Napoletano C, Rughetti A, Nuti M, Mezi S, Marchetti P. Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. Cancer Immunol Immunother. 2023 Jul;72(7):2217-2231. doi: 10.1007/s00262-023-03384-9. Epub 2023 Mar 3. PMID: 36869232; PMCID: PMC10264536.
8. Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. Oncologist. 2023 Nov 23:oyad308. doi: 10.1093/oncolo/oyad308. Epub ahead of print. PMID: 37995313.
9. Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Scagnoli S, Pisegna S, Alesini D, Sini V, Orlandi A, Fabi A, Piacentini F, Moscetti L, D'Auria G, Gamucci T, Mazzotta M, Pizzuti L, Vici P, Cretella E, Scavina P, La Cesa A, Persano M, Atzori F, Ruggeri EM. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study. Front Oncol. 2023 Jun 27;13:1177681. doi: 10.3389/fonc.2023.1177681. PMID: 37441419; PMCID: PMC10335743.
10. Minuti G, Stefani A, Trodella L, Antonini Cappellini G, Cecere F, Dionisi F, Di Salvatore M, Mariotti S, Mazzarella C, Nelli F, Pisegna S, Ricciardi S, Russano M, Ramella S, Bria E, Cappuzzo F. Gestione del paziente con microcitoma a stadio esteso. L’importanza della collaborazione tra oncologia e radioterapia [Management of the patient with extensive stage microcytoma. The importance of collaboration between oncology and radiotherapy.]. Recenti Prog Med. 2023 Jul-Aug;114(7):414-425. Italian. doi: 10.1701/4062.40460. PMID: 37392104.
11. Cerbelli B, Cirillo A, Pomati G, Pernazza A, Ascione A, Pisegna S, Pisano A, Leopizzi M, Pignataro MG, Costarelli L, Mulè A, Vecchione A, Catalano P, Coppola L, Perrone G, Perracchio L, Anemona L, Mastracchio A, Nardi S, Reitano R, Massari A, Grillo LR, Liberati F, Della Rocca C, Marchetti P, Botticelli A, D'Amati G. PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey. Tumori. 2023 Sep 19:3008916231196781. doi: 10.1177/03008916231196781. Epub ahead of print. PMID: 37726962.
12. Fabi A, Ciccarese M, Scagnoli S, Russillo M, Schettini F, Buono G, Lorusso V, Cannita K, Arpino G, Stani S, Palleschi M, Rossello R, Sarobba G, Fabbri A, Giampaglia M, Pellegrini P, Adamo V, Morelli F, Barberi V, Ferretti G, Catania G, Pisegna S, Cognetti F, Giannarelli D. Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice? Oncology. 2021 Dec 7. doi: 10.1159/000521252. Epub ahead of print. PMID: 34875670.
13. Nelli F, Fabbri A, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Berrios JRG, Scagnoli S, Pisegna S, Cirillo A, Panichi V, Massari A, Silvestri MA, Ruggeri EM. Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study. Front Oncol. 2023 Nov 7;13:1280416. doi: 10.3389/fonc.2023.1280416. PMID: 38023235; PMCID: PMC10662103.
14. Mezi S, Botticelli A, Scagnoli S, Pomati G, Fiscon G, De Galitiis F, Di Pietro FR, Verkhovskaia S, Amirhassankhani S, Pisegna S, Gentile G, Simmaco M, Gohlke B, Preissner R, Marchetti P. The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma. Cancers (Basel). 2023 Sep 15;15(18):4587. doi: 10.3390/cancers15184587. PMID: 37760556; PMCID: PMC10526382.
INVITED TALKS
-YO Breast 27.05.2021, webinar. Relazione: paziente post menopausa endocrino-sensibile
-BREAST TALENT 3.0, 18.03.2022, webinar. Relazione: Cosa è cambiato nell’algoritmo terapeutico della malattia HR+, HER2-
-Gestione del paziente con microcitoma a stadio esteso. 10.11.2022 Relazione: ruolo della radioterapia wholebrain vs SBRT.
-Dallo studio clinico al real world: nuove tecnologie e nuovi dati nel carcinoma mammario
26.11.2022; webinar. Relazione: paziente anziana con malattia HR+ endocrinosensibile
-Casi Difficili in Oncologia di precisione relazione: Paziente affetto da neoplasia con mutazione NTRK, webinar 02.12.2022
-Congresso nazionale AIOM giovani, 07.07.2023 “Carcinoma della mammella e test somatico multigene, promessa o miraggio?”
-From S Antonio to Rome, AIOM Lazio, 16.02.2023 “Young and adjuvant treatment”
Regular participation to several naional and International Congresses. In 2023 partecipation to: ESMO congress 2023 (Madrid), San Antonio Breast cancer Syposium (Texas, USA), AIOM 2023 national congress (Rome). In 2022: ESMO congress 2022 Paris (online), ASCO congress 2022 (online); ESMO breast congress 2022 (online); AIOM 2022 national congress, Rome.
AWARDS: Excellent graduated aa 2014-2015, “Sapienza”, Università di Roma